Abstract Stem cell therapy (SCT) raises the hope for cardiac regeneration in ischemic hearts. However, underlying molecular mechanisms for repair of dead myocardium by SCT in the ischemic heart is poorly understood. Growing evidences suggest that cardiac matrix stiffness and differential expressions of miRNAs play a crucial role in stem cell survival and differentiation. However, their roles on transplanted stem cells, for myocardial repair of the ischemic heart, remain unclear. Transplanted stem cells may act in an autocrine and/or paracrine manner to regenerate the dead myocardium. Paracrine mediators such as stem cell-derived exosomes are emerging as a novel therapeutic strategy to overcome some of the limitations of SCT. These exosomes carry microRNAs (miRNAs) that may regulate stem cell differentiation into a specific lineage. MicroRNAs may also contribute to stiffness of surrounding matrix by regulating extracellular matrix (ECM) turnover. The survival of transplanted stem cell depends on its autophagic process that maintains cellular homeostasis. Therefore, exosomes, miRNAs, extracellular matrix turnover, and autophagy may have an integral role in improving the efficacy of SCT. This review elaborates the specific roles of these regulatory components on cardiac regeneration in the ischemic heart during SCT.
Introduction
Ischemic heart disease is a leading cause of mortality in the world. As per the 2012 World Health Organization report 7.4 million people die due to ischemic heart disease (http://www. who.int/mediacentre/factsheets/fs310/en/). Restricted blood supply to the ventricular muscles due to narrowing of coronary arteries results in ischemia that compromises oxygen supply to cardiomyocytes and other cells in the myocardium. Severe ischemia leads to acute myocardial infarction (MI) that results in massive loss of cardiomyocytes [1] . The adult mammalian heart does not have adequate regenerative capacity to replenish the loss of damaged myocardium after MI. Therefore, MI leads to heart failure [2] . Stem cell therapy (SCT) provides a strategy to regenerate new myocardium to replenish dead/damaged myocardium of MI hearts by using exogenous stem cell transplantation [3, 4] . However, the survival, proliferation, and differentiation of transplanted stem cells depend on several factors including the stiffness of extracellular matrix (ECM) surrounding the stem cells [5] [6] [7] [8] [9] [10] . Proteolysis of ECM by matrix metalloproteinase (MMPs) is common in cardiovascular disease (CVD) [11] . MMP9 plays an important role in ECM degradation in pathological hearts that leads to cardiac fibrosis, a stiffer ECM, that may influence cardiac stem cell survival and differentiation [8] . MMPs are regulated by microRNAs (miRNAs) [12, 13] . MiRNAs are tiny non-coding RNAs that regulate biological functions of a cell by modulating expression of genes [14] . MiRNAs have emerged as a novel therapeutic target for CVD [15] [16] [17] . MiRNAs may play a pivotal role in stem cell survival because they regulate stem cell autophagy [18, 19] . Autophagy is a lysosomal degradation process that regulates cellular homeostasis [20] . MiRNAs may regulate cardiac stem cell proliferation and differentiation [21] by acting in an autocrine and/or a paracrine fashion [22, 23] . MiRNAs encapsulated in an exosome circulate through blood and may have a paracrine effect [24] . Exosomes are lipid bilayer nanovesicles released by different types of cells when endosomes carrying multivesicles fuse with plasma membrane. Exosomes exert their therapeutic actions by involving cell-cell interactions and transferring proteins, RNAs [25] , and miRNAs [23] . Exosomes derived from cardiac stem cells is a promising therapeutic candidate because in one hand it may regulate survival, proliferation and differentiation of the transplanted stem cells whereas on the other hand it may overcome the limitations of SCT due to immune rejections, teratoma, or ethical concerns. In this review, we elaborated the roles of exosomes, miRNAs, autophagy, and extracellular matrix turnover in cardiac regeneration during stem cell therapy in the ischemic heart. 
Stem Cell Characteristics and Types

Regulators of CSCs Proliferation and Differentiation
The adult heart has small number of CSCs that may have potential for cardiac regeneration [35] [36] [37] . Stem cells can be differentiated into cardiomyocytes with the treatment of a specific combination of factors [38] . CSCs were identified and validated using various markers such as c-Kit, MDR-1, and Sca-1 [36, 38, 39] . They are heterogeneous and express 7 %-10 % of important cardiogenic transcription factors like Nks2.5, GATA4, and MEF2 [36] . CSCs can divide both symmetrically and asymmetrically, however, asymmetrical division is predominant [40] . They regulate myocytes turnover, which is heterogeneous across the heart. Myocytes turnover is faster at the apex and atria and slower at the base-and midregions of the ventricle [38, 41] . The studies on CSCs differentiation were performed primarily on mice and chick embryos. Several transcription factors regulates differentiation of pluripotent stem cells (PSCs) into cardiac fate. These transcription factors include T Brachyury for primitive streak mesoderm, mesoderm posterior 1(Mesp-1) for cardiogenic mesoderm, and Nkx2.5, T-box (Tbx5/20), GATA4, MEF2C, and Hand1/2 for cardiac mesoderm [53] [54] [55] [56] [57] . Cardiac development is a complex process that is tightly controlled by the sequential expression of multiple signal transduction proteins and transcription factors working in a synergistic manner. The most studied of these growth factors and signaling pathways include FGFs, BMPs, and Wnts/Nodal [58] [59] [60] [61] . We have summarized few of the important regulators of stem cells proliferation and differentiation in Fig. 1 .
Role of Autophagy in Homeostasis of Stem Cells
Autophagy is an evolutionary conserved adaptive process required for cellular homeostasis and protecting against various pathological conditions including CVD. During autophagy defective cytoplasmic cargoes are sequestered into a double membrane autophagosome which after fusion with lysosome are degraded and recycled [20] . Autophagy maintains the quality control of stem and progenitor cells [62] . Various properties of stem cells such as pluripotency, quiescence, differentiation, and self-renewal depend on autophagy activation [63, 64] . Therefore, autophagy plays an important role in normal functions of stem and progenitor cells [65] . Suppression of autophagy through fibroblast growth factor (FGF) signaling inhibits CSC differentiation [65] . Autophagy may have different role in different types of stem cells. It induces apoptosis in BM-MSCs of non-obese diabetic (NOD) mice [66] but promotes MSC-mediated hepatic regeneration in carbon tetrachloride-injured rat liver model [67] , and MSC-mediated wound healing in diabetic mellitus patients [68] .
Trans-Differentiation of Cells
Although differentiation of stem cells into a particular lineage is canonically the strategy for SCT, recent studies revealed that differentiated adult cells can be trans-differentiated into another phenotype by using certain factors. Fibroblasts are present in a large pool in the postnatal heart and they contribute to pathological remodeling via fibrosis. It is observed that by using developmental transcription factors (Gata4, Mef2c, and Tbx5) somatic fibroblast can be reprogrammed into cardiomyocytes in mouse heart [69] . In neonatal and adult humans' fibroblasts addition of Gata4, Hand2, Tbx5, myocardin, miR-1 and miR-133 result in trans-differentiation of fibroblast into cardiomyocyte phenotype [70] . There are several other factors documented in this transdifferentiation process [71, 72] . However, whether these transdifferentiated cardiomyocytes can maintain the cardiomyocyte properties including contractility for prolonged time and can maintain synchronous beating with resident cardiomyocytes is unclear and requires further investigation.
Effect of Extracellular Matrix Turnover on Stem Cell Differentiation
The mechanical force of ECM may influence survival, proliferation, and differentiation of stem cells, and also transdifferentiation of other cells into cardiomyocytes. The mechanical load of the ECM contributes to differentiation of MSCs [73] [74] [75] [76] . Transforming growth factor-beta (TGF-β) promotes MSC differentiation into a smooth muscle lineage on stiff substrates [77, 78] . Soft matrix promotes MSC differentiation into chondrogenic and adipogenic lineages. However, matrix stiffness may not be specific for only one lineage. Biochemical factors such as TGF-β are required to define a unique differentiation pathway [79] . ECM stiffness depends on matrix turnover, which is determined by the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) [80] . MMP-9 and TIMP-4 are predominantly involved in cardiac remodeling. MMP-2 and MMP-9 are collagenases that degrade ECM and contribute to fibrosis [80, 81] , where ECM is stiffer (Fig. 2) . Stiffness of cardiac ECM may play a pivotal role in stem cell therapy [82] . MMP9 is also involved in inhibiting EPCsmediated increase in vessel density in the peri-infarct area in the mouse brain [83] . Moreover, it is implicated in migration of c-Kit + CSCs, which is partially mediated by stem cell factor (SCF) via the activation of PI3K/AKT/MMP-2/−9 signaling pathway [84] . These reports indicate diverse roles of MMPs. Along with MMPs, it was reported that various miRNA family members also regulate ECM. These miRNAs have either pro-, or anti-fibrotic roles in various tissues [85] . stem cell proliferation and differentiation [86] . They have emerged as a biomarker and a therapeutic target for cardiovascular diseases [15, 87, 88] . MiR-29 is found to be an important regulator of TGF-β and collagen synthesis [85] . MiR-1, miR-24, miR-29b, miR-101, and miR200b are anti-fibrotic, whereas miR-15 family, miR-21, miR-34a, miR-192, miR-199b, and miR-208 are profibrotic miRNAs [85] . As discussed above fibrosis changes the ECM tensile properties, and ECM related miRNAs can influence stem cell physiology in normal and pathological conditions. In Table 1 , we have shown the list of miRNAs targeting important ECM regulators including MMPs, TIMPs, CTGF, and TGF-β . The information is obtained from online database miRTarbase (http://mirtarbase. mbc.nctu.edu.tw/).
MicroRNAs in Stem Cell Proliferation and Differentiation
MicroRNAs (miRNAs) regulate differentiation of stem cells into cardiomyocytes [136] . MiR-1 induces differentiation of mESCs and hESCs into cardiac phenotype [51, 137] . MiR-1 promotes differentiation of stem cell by targeting HDAC4, which is a negative regulator of MEF2, whereas miR-133 promotes stem cell proliferation by targeting SRF. The differential expression of miRNAs in ESCs and CSCs is nicely reviewed by Kuppusamy et al. [138] . MiR-1, miR-21, miR-133a, miR-133b, and miR-145 are upregulated both in mouse and human ESC differentiation into cardiac lineage, whereas miR-20b is downregulated during this process in both species [138] . Empirical evidences demonstrate that several miRNAs are deregulated during differentiation of embryonic stem cells into cardiac stem cell lineage [138] [139] [140] [141] . It is also reported that miR-499 along with miR-1 and miR-208 regulates cardiomyocyte differentiation [141] . MiR-133-a, −b, miR-125-a, −b, miR-126, miR-23-a, −b, miR-24, miR -30C, miR-132 are differentially expressed during mouse CSC differentiation [142] . There are several miRNAs that regulate both ECM turnover (Table 1) and stem cell differentiation. MiR-1, miR-21-5p, miR-26a-5p, miR-26b-5p, miR-30c-2-3p, miR-126-3p, miR-126-5p, miR-145-5p, miR-30a, miR30b, miR-99b, miR-125a-5p, miR-129-3p, miR-133a, miR133b, miR-148a, miR-181b, miR-652 are upregulated whereas miR-17-5p, miR-124-3p, miR-200c-3p, miR-205-5p, miR20a, miR-20b, miR-106a, miR-106b, miR-182, miR-183, miR-183*, miR-302c, miR-302c* are downregulated during differentiation of SC into cardiomyocytes [138, 141] . MiRNAs which are involved in regulating ECM turnover include let-7e-5p [122] , miR-100-5p [104] , miR-103a-3p [119] , miR-125b-5p [107] , miR-132-3p [109] , miR-140-5p [106] , miR-143-3p [108] , miR-144-3p [119] , miR-16-5p [122] , miR-181b-5p [117] , miR-18a-5p [130] , miR-18b-5p [122] , miR-19a-3p [135] , miR-19b-3p [130] , miR-203a [102] , miR-221-3p, miR-222-3p [117] , miR-24-3p [123] , miR-27a-3p [106] , miR-27b-3p [105] , miR-29b-3p [143] , miR-335-5p [97] , miR-338-3p [94] , miR-375 [134] , miR-423-5p [122] , miR-451a [92] , miR-491-5p [93] , miR-519a-3p, miR-519c-3p, miR-519d-3p [110] , miR-633, miR-663a [126] , miR-9-5p [103] . Therefore, miRNAs play an integral role in SCT (Fig. 3) . In healthy heart collagen and elastin are present in optimal ratio which might help in maintaining the integrity of ECM and niche of stem cells. In failing heart activity of MMPs is augmented, expression of cardio-protective miRNAs is attenuated, stiffness of ECM and apoptosis of stem cells are induced. 
MicroRNAs in Trans-Differentiation
Cardiac fibroblasts can be reprogrammed to cardiomyocytes using combination of different miRNAs (miR-1, miR-133, miR-208 and miR-499) [144] . Administration of these miRNAs into ischemic boarder zone of MI heart induces trans-differentiation of cardiac fibroblasts into cardiomyocytes. Although miR-1 may be sufficient to induce cardiomyocyte trans-differentiation, the combination of miR-133, −208, and −499 is much more effective in the trans-differentiation process. Fibroblast-turned cardiomyocytes have all the properties of functional cardiomyocytes including contractility and spontaneous calcium oscillations [144] . Therefore, transdifferentiation of fibroblasts into cardiomyocytes by miRNAs provides a novel opportunity for SCT.
Stem Cell Therapy for Cardiac Regeneration
Stem cell therapy (SCT) is one of the propitious approaches to promote cardiac regeneration or repair myocardium after MI [145, 146] . Growing evidence suggest that cardiac regeneration by SCT is influenced by several paracrine factors [156, 157] . Moreover, the homing of transplanted stem cells is dictated by the cytokines released from the damaged tissue [158] . Broad range of cytokines, chemokines, growth factors such as vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), insulin-like growth factor-1 (IGF-1), and hepatocyte growth factor (HGF) have been shown to stimulate regeneration. Exosomes are one of the various paracrine mediators, which play an important role as regulator in cell autonomous repair mechanisms [159] .
Role of miRNA Containing Exosomes in Cardiac Regeneration
Exosomes originate from inward folding of cell membranes which results in the formation of multiple intraluminal vesicles in the endosome called multivascular bodies (MVBs). These MVBs fuse with the plasma membrane releasing intraluminal vesicles into the extracellular matrix in the form of exosomes [160] [161] [162] . They are present in the extracellular space as vesicles [160] . The diameter of exosome range from 30 to 120 nm. Exosome is first reported in sheep reticulocytes in early 1950s [162, 163] . They are secreted from various types of cells including stem cells [164] , cardiomyocytes [165] , B cells [166] , T cells [167] , dendritic cells [168] , platelets [169] , Schwann cells [170] , endothelial cells [171] , and tumor cells [172] . They are present in various body fluids such as blood, urine, plasma, semen, and broncho-alveolar lavage, and play an important role in intercellular communication [173, 174] . They also play a pivotal role in modulating of immune responses and cell signaling pathways [175] [176] [177] . Different types of exosomes behave differently based on their origin. Stem cell exosomes are released by different types of stem cells such as pluripotent stem cells (embryonic stem cells-and induced pluripotent-derived exosomes) and adult stem cells (mesenchymal-, endothelialprogenitor-, and cardiac progenitor-derived exosomes). The roles of stem cell exosomes on cardiac repair along with their roles in normal and infarcted heart are documented [162, 178] . Exosomes released during stress or pathological conditions behave differently compared to healthy conditions [179] . ESCs serve as a promising source of exosomes due to their unique microRNA and protein content to augment endogenous CPCs proliferation and differentiation. MiR-290 family is highly expressed in ESC-derived exosomes in the mouse cardiomyocytes, which is evident from the elevated levels of miR-291, miR-294 and miR-295. These exosomes might have an important role in ESC exosome-mediated cardiac repair. Therefore, these exosome are implicated in stem cell survival, proliferation, and differentiation into cardiomyocyte lineage [180] . Few studies have reported cardioprotective effects of CPC-derived exosomes in myocardial ischemia/reperfusion (I/R) injury and MI model. CPC exosomes with miR-451/ 144 might exert beneficial effects [181] . They also enhanced endothelial cell migration through extracellular matrix metalloproteinase inducer (EMMPRIN) [165] . Exosomes with various miRNAs derived from CPCs in hypoxic conditions improve cardiac function in the injured heart [182] . Cardiosphere derived cell (CDC) exosomes with miR-146a have elicited signature beneficial effects in MI model by improving global function and decreasing scar mass. Though therapeutic regeneration was observed with miR-146a-treated hearts but CDC exosomes excel in having more promising effects [183] . CDC exosomes carrying miR-22 and miR-24 played a prominent role in cardiac regeneration [184, 185] . Exosomes are also released from mature cells present in the heart such as cardiomyocytes and fibroblasts [186, 187] . MiR-320 enriched exosomes in diabetic cardiomyocytes transfer miR-320 into endothelial cells and inhibit endothelial cell proliferation, migration, and myocardial angiogenesis in diabetics [187] .
Stem Cell Therapy and Stem Cell-Derived Exosomes in Clinical Trial
The first stem cell based clinical trial with intracoronary infusion was "transplantation of progenitor cells and regenerative enhancement in acute myocardial infarction (TOPCARE)", where bone marrow-derived mononuclear cells (BMMNCs) were used [188] . Although, there was initial success with this population of cells for acute myocardial infarction (AMI) and chronic heart failure (CHF) but later in larger trials, no significant improvement in heart condition was observed [188] . Subsequent clinical trials were based on purified cell population. In Act34-CMI trial, CD34+ EPCs were used for chronic myocardial infarction (CMI) and reduction in frequency of angina was reported. However, in another trial (POSEIDON) using purified BM derived human MSCs, no improvement in ejection fraction was observed in patients [188] . Cardiac specific stem cells were used in recently concluded SCIPIO trial. It is reported that c-kit + , lineage negative CSCs improve postinfarction left ventricular functions [156] . However, another group found that c-kit + cells have minimal contribution to cardiomyocytes in the adult heart [189] . There is controversy on whether c-kit + cells are the marker of cardiac stem cells [190] . CADUCEUS clinical trial used CSC cardiosphere and observed no cardiac benefits in AMI patients whereas C-CURE trial used cardiopoietic hMSCs and reported positive results in ischemic cardiomyopathy patients [188] . Apart from various phase-I and II clinical trials, there are few ongoing phase-III clinical trials -BMI, CHART-1, CHART-2. The BMI trial used BMMNCs whereas CHART-1 and 2 used MSCs isolated from patient's bone marrow [188] . Clinical trials on human ESCs and iPSCs in various ailments is reviewed [191] . Transcoronary infusion of CPCs in patients with hypoplastic left heart syndrome, the (HLHS)-TICAP trial showed improvement in right ventricular ejection fraction that persisted during 36-month follow up [192] . A list of existing and ongoing stem cell clinical trials are summarized in a recent review by Poulin et al. [193] .
Limitations and Future Perspective of Stem Cell Therapy
Although several types of stem cells were used in clinical trials, they were successful only at different phases of clinical trials but mostly failed in larger trials, may be due to inappropriate choice of endpoints and/or less considerations for regulatory pathways involved in myocardial regeneration [194] . Careful analyses of results from clinical trials will help us to understand the challenges to get success in stem cell therapy for heart failure [195, 196] . To understand the cause of failure of larger clinical trial, it is imperative to evaluate the gene expression profiles of the transplanted stem cells after engraftment and to develop strategies that can facilitate the engraftment and differentiation of transplanted stem cells. The success of stem cell therapy may depend on homing and differentiation of transplanted stem cells to cardiac lineages that contribute to myocardial regeneration, the effect of paracrine Fig. 4 Schematics of systemic approach for stem cell therapy. Improved cardiac regeneration can be achieved by using different approaches such as regulating autophagy in stem cells, using stem cell-derived exosomes, inhibiting matrix metalloproteinase-9 (MMP9) that may reduce stiffness of extracellular matrix to promote stem cell proliferation and differentiation, and inducing trans-differentiation of fibroblasts into cardiomyocytes.
factors that stimulate endogenous resident stem cell's differentiation to contribute to myocardial regeneration, and the microenvironment surrounding the niche of the stem cells that facilitates survival and differentiation of stem cells [86, 197] . Recent studies demonstrated that stem cell exosomes could be a promising target for myocardial regeneration, and several preclinical trials reported improvement in myocardial regeneration by stem cell exosomes [164, [198] [199] [200] . Therefore, exosomes could be a novel approach for cardiac regeneration [201] , and are given in pre-clinical studies for evaluating its safety and efficacy. MiRNAs from these exosomes can be also used as a biomarker [202] . Although miRNAs are now in clinical trials [203] , stem cell-derived exosomes need further investigations to translate its role in SCT. One of the limitations of exosome-mediated cardiac regeneration is specificity and yield of exosomes [204] . Developing techniques to isolate cardiac specific exosomes, their delivery to the border zone of the ischemic heart, and understanding the mechanism of action of exosomes delivered to the ischemic heart are some of the strategies for successful use of exosomes in regenerating damaged myocardium. An alternative strategy for replenishing the dead myocardium could be trans-differentiation of fibroblast into functional cardiomyocytes or inducing cardiomyocyte to reenter into cell cycle [205] . Considering of ECM stiffness and its impact on stem cells, regulation of MMPs especially inhibition of MMP9 can be an important approach. Similarly, regulation of autophagy of stem cells is crucial for their survival and differentiation.
In summary, we can harness the basic science knowledge and clinical outcomes from the previous clinical trials to understand the factors that regulate survival of transplanted stem cells, differentiation of engrafted stem cells into a specific lineage such as cardiomyocytes, maintenance of cardiomyocyte's properties for prolong time. At the same time, we need to use systematic approach to improve cardiac regeneration in MI hearts and it may include autophagy, exosome, miRNAs, ECM stiffness, and trans-differentiation (Fig. 4) .
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